CollPlant Announces Encouraging Data From Comparative Study Of Collink.3D And Matrigel

(RTTNews) - CollPlant Biotechnologies Ltd. (CLGN), Monday announced encouraging results from a head-to-head comparative study of its rhCollagen-based bioink, Collink.3D, and Matrigel, developed and marketed by Corning.

Conducted by Levenberg Lab at Technion - Israel Institute of Technology, the study demonstrated Collink.3D's enhanced mechanical strength, elasticity, and stability, suggesting that it may serve as a next-generation, animal-free extracellular matrix.

CEO Yehiel Tal noted, "The results reinforce Collink.3D as a biologically supportive and durable bioink that promotes cell organization and tissue development while maintaining structural integrity over time."

In the pre-market hours, CLGN is trading at $2.39, up 3.02 percent on the Nasdaq.